More search options
Basket icon
No items
Basket icon

Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. BME1
Subject category: Ethics and Social Responsibility
Authors: Margaret L Eaton (Stanford Graduate School of Business, Stanford University); Jennifer Wilds (Stanford Graduate School of Business, Stanford University); Betty Pang (School of Medicine, Stanford University)
Published by: Stanford Business School
Originally published in: 2004
Version: 15 February 2005
Length: 23 pages
Data source: Field research
Topics: Ethics; Pharmaceuticals
Share a link: https://casecent.re/p/87149
| No reviews for this item
This product has not been used yet
View our pricing guide or login to see prices.

Abstract

The case details the efforts of VaxGen and its President, Don Francis, to obtain approval to conduct Phase III clinical trials in Thailand for AIDSVAX, an experimental vaccine designed to protect against human immunodeficiency virus (HIV), the virus that causes AIDS. Francis must grapple with a host of ethical questions, from how certain he needs to be of the effectiveness of AIDSVAX to warrant the involvement of thousands of subjects in clinical trials, to what type of compensation or treatment, if any, to offer to volunteer subjects in developing countries where the standard for AIDS treatment is much lower than in the United States.
Location:
Corporate headquarters in South San Francisco and Bangkok
Teaching note
-
Reference no. BME1TN
Subject category: Ethics and Social Responsibility
Authors: Jennifer Wilds (Stanford Graduate School of Business, Stanford University); Betty Pang (School of Medicine, Stanford University); Margaret L Eaton (Stanford Graduate School of Business, Stanford University)
Published by: Stanford Business School
Originally published in: 2004
Version: 15 February 2005
Length: 2 pages
Data source: Field research
View full details

About

Abstract

The case details the efforts of VaxGen and its President, Don Francis, to obtain approval to conduct Phase III clinical trials in Thailand for AIDSVAX, an experimental vaccine designed to protect against human immunodeficiency virus (HIV), the virus that causes AIDS. Francis must grapple with a host of ethical questions, from how certain he needs to be of the effectiveness of AIDSVAX to warrant the involvement of thousands of subjects in clinical trials, to what type of compensation or treatment, if any, to offer to volunteer subjects in developing countries where the standard for AIDS treatment is much lower than in the United States.

Settings

Location:
Corporate headquarters in South San Francisco and Bangkok

Related

Teaching note
-
Reference no. BME1TN
Subject category: Ethics and Social Responsibility
Authors: Jennifer Wilds (Stanford Graduate School of Business, Stanford University); Betty Pang (School of Medicine, Stanford University); Margaret L Eaton (Stanford Graduate School of Business, Stanford University)
Published by: Stanford Business School
Originally published in: 2004
Version: 15 February 2005
Length: 2 pages
Data source: Field research
View full details